Skip to main content

Market Overview

Veru: Q2 Earnings Insights

Share:

 

Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estimate of ($0.04).

Revenue of $13,340,000 higher by 34.16% from the same period last year, which missed the estimate of $14,290,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 12, 2021

Time: 08:00 AM

ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=VV1xc3KL

Technicals

Company's 52-week high was at $24.57

52-week low: $2.30

Price action over last quarter: down 60.22%

Company Description

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.

 

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com